by Manon FRACHON | 8 Jul Wed | Without category
Magdalena Jonikas brings 15 years of international biopharma experience across strategy, investing and operating. Her commercially driven, scientifically grounded approach, together with her track record in company creation, and board and portfolio company leadership,...
by Manon FRACHON | 22 Jun Mon | Without category
The financing aims to accelerate the development of near-clinical and clinical drug candidates offering targeted treatments designed to maximize efficacy in severe inflammatory diseases (including atopic dermatitis and inflammatory bowel disease (IBD)), where...
by Manon FRACHON | 12 May Tue | Without category
Jeito[1] reaffirms its commitment by participating in the IPO, following its significant investment in Odyssey’s recent oversubscribed $213 million series D financing round This renewed support underscores the company’s innovation potential for patients with...
by Manon FRACHON | 14 Apr Tue | English
Proceeds from the financing will support the advancement of three first- and best-in-class ADC[1] programs through upcoming key clinical milestones While oncology continues to face substantial and largely unmet needs, Jeito will leverage its expertise to accelerate...
by Manon FRACHON | 11 Mar Wed | Without category
Samit Hirawat, M.D., brings over 25 years of senior leadership and clinical development experience at top-tier international pharmaceutical groups, including Novartis and Bristol Myers Squibb, further enhancing Jeito’s strategic capabilities. His expertise will...
Recent Comments